Chapter VIII

References
References:


Bornstein J, Lawrence RD. (1951) Plasma Insulin in Human Diabetes Mellitus. BMJ 2, 1541.


**Campbell IW.** *(2000)* Antidiabetic drugs past and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 60(5), 1017-1028.

**Ceriello A.** *(2005)* Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 54(1), 1-7.


**Chan JC, Chan KW, Ho LL.** *(1998)* An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 21(7), 1058-1061.

**Chan JC.** *(2009)* Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301, 2129–2140.


REFERENCES


Davis SN, Johns D, Maggs D, Xu H, Northrup JH, and Brodows RG. (2007) Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents Diabetes Care 30(11), 2767-2772.


carotid arteries in subjects with impaired glucose tolerance. Stroke 35, 1073-1078.


linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 11, 786–794.


ICMR Guidelines for Management of Type 2 Diabetes- 2005.


International Diabetes Federation, Update 2012. IDF Diabetes Atlas..


National Diabetes Fact Sheet (2011) 1-12.


REFERENCES


REFERENCES


